Skip to main content
TipRanks
Go Ultimate75% OFF

Radnet (RDNT) AI Stock Analysis

412 Followers
RDNT

Radnet

(NASDAQ:RDNT)

Select Model
Rating:57Neutral
Price Target:$79.00â–²(5.45% Upside)
Action:reiterated
Date:11/10/26

The score is held back primarily by weaker financial performance (net losses, thin margins, high leverage, and negative TTM free cash flow). Offsetting this, the latest earnings call was notably constructive with raised guidance, strong liquidity, and visible growth drivers, and technicals also show a supportive uptrend. Valuation remains a modest negative given the loss-driven negative P/E and lack of dividend support.

Positive Factors
Revenue and operating growthRecord revenue and adjusted EBITDA, alongside higher guidance, indicate that RadNet is converting capacity expansion, advanced-imaging mix and operational improvements into scalable growth. This supports stronger reinvestment capacity and suggests the core imaging platform can compound over the next several quarters.
Negative Factors
Elevated leverageMeaningful leverage reduces financial flexibility and leaves more operating cash committed to debt service and refinancing needs. Because current losses make deleveraging harder, RadNet may have less capacity to absorb setbacks or fund expansion internally if earnings recovery slows.

Radnet (RDNT) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%RDNT-5.48%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.90B
Dividend Yield
―
Average Volume (3M)
677.81K
Price to Earnings (P/E)
-261.6
Beta (1Y)
0.98
Revenue Growth
21.06%
EPS Growth
-70.26%
Country
US
Employees
9,060
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Radnet Business Overview & Revenue Model

Company Description

RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance...

How the Company Makes Money

RadNet primarily makes money by performing diagnostic imaging exams at its outpatient imaging centers and getting paid for those services. Revenue is generally generated on a per-procedure basis and is largely reimbursed by third-party payors (includ...

Radnet Earnings Call Summary

Earnings Call Date:Nov 08, 2026(Q3-2026)|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive. RadNet reported record company revenue and adjusted EBITDA, broad-based imaging volume growth, expanding advanced-imaging mix, raised Imaging Center and Digital Health guidance, strong liquidity, substantial Digital Health bookings and ARR growth, and continued progress in AI deployment and the planned ONRAD acquisition. The main challenges were year-over-year Digital Health EBITDA and margin declines, labor shortages, implementation seasonality and constraints, and expected 2027 Medicare reimbursement pressure, but management characterized the implementation constraints as resolved and remained confident about fourth-quarter and 2027 growth.

Positive Updates

Record Third-Quarter Revenue and Adjusted EBITDA
Total company revenue reached a quarterly record of $638.3 million, up 22.1% from $522.9 million in last year's third quarter. Adjusted EBITDA also reached a quarterly record of $105 million, up 23.8% from $84.9 million, while adjusted EBITDA margin expanded 23 basis points to 16.5%. Adjusted diluted EPS increased to $0.30 from $0.24.

Negative Updates

Digital Health Adjusted EBITDA Declined Year Over Year
Digital Health adjusted EBITDA was $3 million, compared with $3.5 million in last year's third quarter. Management attributed the decline to continued investment in commercial and implementation headcount and temporary margin dilution from recent acquisitions, including GLEAMER.

Company Guidance

For 2026, Imaging Center segment total net revenue guidance is $2.385 billion to $2.435 billion, adjusted EBITDA guidance is $350 million to $363 million, capital expenditure guidance is $170 million to $180 million, and free cash flow guidance is $120 million to $130 million; Digital Health revenue guidance is $135 million to $145 million, while adjusted EBITDA guidance is $10 million to $13 million and adjusted EBITDA before noncapitalized R&D guidance is $11 million to $13 million, with Digital Health CapEx guidance increased by $1 million. Digital Health is on track for more than $140 million of ARR by year-end, roughly 87% growth over 2025, expects fourth quarter revenue to grow about 20% sequentially, and indicated a fully underpinned fourth quarter of well above $40 million; ONRAD is expected to add $190 million to $200 million of revenue and $60 million to $65 million of adjusted EBITDA in its first year of operation after closing. For 2027, RadNet estimated an approximately $5 million revenue impact from the final Medicare rule, while noting Congress may act to partially or fully reverse this reduction.

Radnet Financial Statement Overview

Summary

Strong revenue growth and solid operating cash flow are outweighed by thin/compressing margins, recent net losses, elevated leverage (debt-to-equity ~1.94x), and a swing to negative TTM free cash flow (-$155M), which limits financial flexibility despite improving scale.

Income Statement

44Neutral

Balance Sheet

46Neutral

Cash Flow

41Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.38B2.04B1.83B1.62B1.43B1.32B
Gross Profit233.49M90.80M249.12M221.39M165.72M191.80M
EBITDA295.20M253.95M262.55M292.79M278.53M278.37M
Net Income-22.38M-18.65M2.79M3.04M10.65M24.73M
Balance Sheet
Total Assets4.28B3.76B3.29B2.69B2.43B2.06B
Cash, Cash Equivalents and Short-Term Investments750.61M767.22M740.02M342.57M127.83M134.61M
Total Debt2.17B1.86B1.73B1.49B1.51B1.40B
Total Liabilities2.84B2.40B2.15B1.88B1.94B1.71B
Stockholders Equity1.12B1.09B902.31M630.70M333.00M228.90M
Cash Flow
Free Cash Flow-155.28M85.57M44.95M44.26M-103.00M-71.20M
Operating Cash Flow341.47M298.82M233.02M220.86M146.42M149.49M
Investing Cash Flow-601.56M-343.87M-233.07M-201.47M-246.95M-221.51M
Financing Cash Flow207.97M72.21M397.95M195.63M93.65M104.67M

Radnet Technical Analysis

Technical Analysis SentimentPositive
Last Price74.92

Price Trends

50DMA72.90Positive
100DMA70.98Positive
200DMA65.43Positive

Market Momentum

MACD1.38Positive
RSI51.31Neutral
STOCH38.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDNT, the sentiment is Positive. The current price of 74.92 is above the 20-day moving average (MA) of 74.63, above the 50-day MA of 72.90, and above the 200-day MA of 65.43, indicating a bullish trend. The MACD of 1.38 indicates Positive momentum. The RSI at 51.31 is Neutral, neither overbought nor oversold. The STOCH value of 38.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDNT.

Radnet Risk Analysis

Radnet disclosed 48 risk factors in its most recent earnings report. Radnet reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We will incur significant transaction and Merger-related costs in connection with the Mergers.Q3, 2026
2.Completion of the Mergers is subject to certain conditions and if these conditions are not satisfied, waived or fulfilled in a timely manner, the Mergers may be delayed or not completed.Q3, 2026
3.Our business relationships may be subject to disruption due to uncertainty associated with the Mergers.Q3, 2026

Radnet Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RDNT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DGXDGX76Outperform$28.20B25.2015.21%1.32%9.13%17.93%
LHLH75Outperform$29.90B30.0911.54%0.78%6.02%19.63%
RDNTRDNT57Neutral$5.90B-261.64-2.04%―21.06%-70.26%
NEONEO54Neutral$1.97B-61.65-3.97%―11.08%71.76%
OPKOPK52Neutral$1.20B-8.41-12.41%―-21.87%18.50%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NDRANDRA42Neutral$5.88M-0.62-224.80%――60.87%

* Healthcare Sector Average

Performance Comparison

-50%0%50%RDNTLHOPKDGXNEONDRADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RDNT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RDNTRadnet74.92-5.37-6.69%
LHLabcorp Holdings Inc.368.24110.3042.76%
OPKOpko Health1.620.3123.66%
DGXQuest Diagnostics256.3573.4740.17%
NEONeoGenomics Inc.15.254.9748.35%
NDRAEndra Life Sciences3.92-2.73-41.05%

Radnet Corporate Events

Business Operations and StrategyM&A Transactions

RadNet to Acquire ONRAD, Expanding Radiology Services Platform

Positive
Oct 26, 2026

On October 26, 2026, RadNet entered into a definitive agreement to acquire ONRAD, Inc., in a cash‑and‑stock deal worth $350 million in cash plus five million RadNet shares at closing, with a potential earn‑out of up to $210 million tied to ONRAD’s 20...

Business Operations and StrategyRegulatory Filings and Compliance

RadNet Registers Shares for See-Mode Milestone Resale

Neutral
Aug 14, 2026

On August 14, 2026, RadNet, Inc. filed a prospectus supplement with the Securities and Exchange Commission to register for resale up to 34,069 shares of its common stock held by certain See-Mode Sellers. These shares will be issued as part of the sha...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026